Freestone Grove Partners LP Editas Medicine, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 36,126 shares of EDIT stock, worth $74,419. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,126Holding current value
$74,419% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding EDIT
# of Institutions
225Shares Held
54.2MCall Options Held
412KPut Options Held
355K-
Black Rock Inc. New York, NY7.78MShares$16 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.82MShares$14.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.75MShares$5.66 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.16MShares$4.45 Million0.0% of portfolio
-
State Street Corp Boston, MA1.87MShares$3.86 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $142M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...